论文部分内容阅读
心血管疾病(CVD)是慢性肾脏疾病(CKD)的重要并发症及透析患者的主要死亡原因,重视CKD患者CVD的防治对于改善其预后至关重要。缺血修饰清蛋白(IMA)是美国国家药品食品管理局批准的反映早期心肌缺血的生化标志物,具有出现早、敏感性高、阴性预测值高等优势,可应用于CVD及CKD并发CVD的早期诊断、危险分层、预后判断等。近年来,国外对IMA在CVD及CKD并发的CVD中的应用研究已广泛开展,而国内对此的研究尚处于起步阶段。
Cardiovascular disease (CVD) is an important complication of chronic kidney disease (CKD) and the main cause of death in dialysis patients. It is important to pay attention to the prevention and treatment of CVD in patients with CKD to improve its prognosis. Ischemia-modified albumin (IMA) is a biochemical marker of early myocardial ischemia approved by the U.S. Food and Drug Administration. It has the advantages of early onset, high sensitivity and high negative predictive value. It can be used in CVD and CKD complicated with CVD Early diagnosis, risk stratification, prognosis and so on. In recent years, foreign applications of IMA in the CVD and CKD concurrent CVD has been widely studied, but the domestic research is still in its infancy.